Vivatides Therapeutics

Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026

Vivatides Therapeutics announced the completion of an oversubscribed USD 54 million Series A financing round,...

Company Deals

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform

Fineline Cube Aug 20, 2025

Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by...

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC